{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:53:45Z","timestamp":1773212025191,"version":"3.50.1"},"reference-count":49,"publisher":"Medwave Estudios Limitada","issue":"Suppl2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medwave"],"DOI":"10.5867\/medwave.2017.6942","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T21:43:19Z","timestamp":1495143799000},"page":"e6942-e6942","source":"Crossref","is-referenced-by-count":6,"title":["Sevelamer versus calcium-based phosphate binders for chronic kidney disease"],"prefix":"10.5867","volume":"17","author":[{"given":"Gonzalo A.","family":"Bravo-Soto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinidad","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3888","published-online":{"date-parts":[[2017,5,17]]},"reference":[{"issue":"2","key":"ref0","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.","volume":"19","author":"Ferreira","year":"2008","unstructured":"Ferreira A, Fraz\u00e3o JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al; Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008 Feb;19(2):405-12 | CrossRef | PubMed |","journal-title":"J Am Soc Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1046-6673","issn-type":"print"},{"issue":"3","key":"ref1","first-page":"176","article-title":"Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.","volume":"14","author":"Gallieni","year":"2001","unstructured":"Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. J Nephrol. 2001 May-Jun;14(3):176-83 | PubMed |","journal-title":"J Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1121-8428","issn-type":"print"},{"key":"ref2","unstructured":"Gallieni M, Cicchetti T, Salvadori M, Stalteri A, Tarchini R. Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial - Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]. 2Journal of American Society of Nephology. 2005;16(746A) | Link |"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.","volume":"52","author":"Garg","year":"2005","unstructured":"Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum. 2005 Jan;52(1):290-5 | PubMed |","journal-title":"Arthritis Rheum","ISSN":"https:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"issue":"9","key":"ref4","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/ndt\/13.9.2303","article-title":"Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.","volume":"13","author":"Goldberg","year":"1998","unstructured":"Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant. 1998 Sep;13(9):2303-10 | PubMed |","journal-title":"Nephrol Dial Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0931-0509","issn-type":"print"},{"issue":"4","key":"ref5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11255-009-9688-9","article-title":"Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4","volume":"42","author":"Gulati","year":"2010","unstructured":"Gulati A, Sridhar V, Bose T, Hari P, Bagga A. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3\u20134. International Urology and Nephrology. 2010;42(4):1055-1062.","journal-title":"International Urology and Nephrology"},{"issue":"85","key":"ref6","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1046\/j.1523-1755.63.s85.17.x","article-title":"Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.","author":"Herv\u00e1s","year":"2003","unstructured":"Herv\u00e1s JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney Int Suppl. 2003 Jun;(85):S69-72 | PubMed |","journal-title":"Kidney Int Suppl","ISSN":"https:\/\/id.crossref.org\/issn\/0098-6577","issn-type":"print"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1774-9987.2005.00210.x","article-title":"Is 2.5 mEq\/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K\/DOQI guidelines.","volume":"9","author":"Izumi","year":"2005","unstructured":"Izumi M, Shirai K, Ito K, Miyamoto T, Matsumoto A, Takenaka Y, et al. Is 2.5 mEq\/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K\/DOQI guidelines. Ther Apher Dial. 2005 Feb;9(1):24-31 | PubMed |","journal-title":"Ther Apher Dial","ISSN":"https:\/\/id.crossref.org\/issn\/1744-9979","issn-type":"print"},{"issue":"4","key":"ref8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1542-4758.2011.00575.x","article-title":"Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the French ARNOS study.","volume":"15","author":"Jean","year":"2011","unstructured":"Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the French ARNOS study. Hemodialysis International. 2011;15(4):485-492. | CrossRef | Link |","journal-title":"Hemodial Int","ISSN":"https:\/\/id.crossref.org\/issn\/1492-7535","issn-type":"print"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.","volume":"57","author":"Kakuta","year":"2011","unstructured":"Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011 Mar;57(3):422-31 | CrossRef | PubMed |","journal-title":"Am J Kidney Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0272-6386","issn-type":"print"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/089686080602600308","article-title":"Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.","volume":"26","author":"Katopodis","year":"2006","unstructured":"Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, et al. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int. 2006 May-Jun;26(3):320-7 | PubMed |","journal-title":"Perit Dial Int","ISSN":"https:\/\/id.crossref.org\/issn\/0896-8608","issn-type":"print"},{"key":"ref11","unstructured":"Kingusa E, Koshikawa S. Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients\u2014A randomized, open label, dose titration study of PB-94 versus Caltan tablet 500 (calcium carbonate). Journal of American Society of Nephology. 2001;12(755A) | Link |"},{"issue":"4","key":"ref12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1744-9987.2005.00294.x","article-title":"Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.","volume":"9","author":"Koiwa","year":"2005","unstructured":"Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial. 2005 Aug;9(4):340-6 | PubMed |","journal-title":"Ther Apher Dial","ISSN":"https:\/\/id.crossref.org\/issn\/1744-9979","issn-type":"print"},{"issue":"11","key":"ref13","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/nep.12319","article-title":"Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.","volume":"19","author":"Lin","year":"2014","unstructured":"Lin HH, Liou HH, Wu MS, Lin CY, Huang CC. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology (Carlton). 2014 Nov;19(11):672-8 | CrossRef | PubMed |","journal-title":"Nephrology (Carlton)","ISSN":"https:\/\/id.crossref.org\/issn\/1320-5358","issn-type":"print"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/11539120-000000000-00000","article-title":"Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study.","volume":"31","author":"Lin","year":"2011","unstructured":"Lin YF, Chien CT, Kan WC, Chen YM, Chu TS, Hung KY, et al. Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. Clin Drug Investig. 2011;31(4):257-67 | CrossRef | PubMed |","journal-title":"Clin Drug Investig","ISSN":"https:\/\/id.crossref.org\/issn\/1173-2563","issn-type":"print"},{"issue":"9","key":"ref15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0929-6646(10)60107-6","article-title":"Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.","volume":"109","author":"Lin","year":"2010","unstructured":"Lin YF, Chen YM, Hung KY, Chu TS, Kan WC, Huang CY, et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. J Formos Med Assoc. 2010 Sep;109(9):663-72 | CrossRef | PubMed |","journal-title":"J Formos Med Assoc","ISSN":"https:\/\/id.crossref.org\/issn\/0929-6646","issn-type":"print"},{"issue":"8","key":"ref16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/08860220600925388","article-title":"A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.","volume":"28","author":"Liu","year":"2006","unstructured":"Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail. 2006;28(8):701-7 | PubMed |","journal-title":"Ren Fail","ISSN":"https:\/\/id.crossref.org\/issn\/0886-022X","issn-type":"print"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000063307","article-title":"Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients.","volume":"92","author":"Marco","year":"2002","unstructured":"Marco MP, Muray S, Betriu A, Craver L, Belart M, Fern\u00e1ndez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron. 2002 Oct;92(2):499-500 | PubMed |","journal-title":"Nephron","ISSN":"https:\/\/id.crossref.org\/issn\/0028-2766","issn-type":"print"},{"issue":"9","key":"ref18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/ndt\/17.9.1643","article-title":"A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.","volume":"17","author":"McIntyre","year":"2002","unstructured":"McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant. 2002 Sep;17(9):1643-8 | PubMed |","journal-title":"Nephrol Dial Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0931-0509","issn-type":"print"},{"issue":"2","key":"ref19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11255-004-7135-5","article-title":"Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride.","volume":"37","author":"Mitsopoulos","year":"2005","unstructured":"Mitsopoulos E, Griveas I, Zanos S, Anagnostopoulos K, Giannakou A, Pavlitou A, et al. Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride. Int Urol Nephrol. 2005;37(2):321-8 | PubMed |","journal-title":"Int Urol Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/0301-1623","issn-type":"print"},{"issue":"9","key":"ref20","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2215\/CJN.01650211","article-title":"Caza-a-P\u00e9rez V, Garc\u00eda-P\u00e9rez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.","volume":"6","author":"Navarro-Gonz\u00e1lez","year":"2011","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C, Muros de Fuentes M, Donate-Correa J, Caza-a-P\u00e9rez V, Garc\u00eda-P\u00e9rez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011 Sep;6(9):2272-9 | CrossRef | PubMed |","journal-title":"Clin J Am Soc Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1555-9041","issn-type":"print"},{"issue":"1","key":"ref21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1774-9987.2005.00215.x","article-title":"Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.","volume":"9","author":"Ogata","year":"2005","unstructured":"Ogata H, Koiwa F, Shishido K, Kinugasa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial. 2005 Feb;9(1):11-5 | PubMed |","journal-title":"Ther Apher Dial","ISSN":"https:\/\/id.crossref.org\/issn\/1744-9979","issn-type":"print"},{"issue":"2","key":"ref22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010 Feb;5(2):286-91 | CrossRef | PubMed |","journal-title":"Clin J Am Soc Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1555-9041","issn-type":"print"},{"key":"ref23","unstructured":"Oliveira R, Cancela E. Sevelamer (SEV), but Not Calcium Acetate (CA), Decreases Serum Fibroblast Growth Factor 23 (FGF23) in Hemodialysis Patients. J Am Soc Nephrol. 2007; | Link |"},{"issue":"5","key":"ref24","first-page":"432","volume":"23","author":"Ortiz","year":"2003","unstructured":"Ortiz A, R\u00edos F, Melero R, Reyero A, Gazapo R, Casado S. [Experience with sevelamer in peritoneal dialysis]. Nefrologia. 2003 Sep-Oct;23(5):432-6 | PubMed |","journal-title":"Nefrologia","ISSN":"https:\/\/id.crossref.org\/issn\/0211-6995","issn-type":"print"},{"issue":"5","key":"ref25","first-page":"556","article-title":"Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study.","volume":"23","author":"Panichi","year":"2010","unstructured":"Panichi V, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, et al. Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study. J Nephrol. 2010 Sep-Oct;23(5):556-62 | PubMed |","journal-title":"J Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1121-8428","issn-type":"print"},{"issue":"3","key":"ref26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1542-4758.2009.00369.x","article-title":"Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients.","volume":"13","author":"Peres","year":"2009","unstructured":"Peres AT, Dalboni MA, Canziani ME, Manfredi SR, Carvalho J, Batista MC, et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International. 2009;13(3):271-277 | CrossRef |","journal-title":"Hemodial Int","ISSN":"https:\/\/id.crossref.org\/issn\/1492-7535","issn-type":"print"},{"issue":"6","key":"ref27","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.","volume":"51","author":"Qunibi","year":"2008","unstructured":"Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008 Jun;51(6):952-65 | CrossRef | PubMed |","journal-title":"Am J Kidney Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0272-6386","issn-type":"print"},{"issue":"5","key":"ref28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).","volume":"65","author":"Qunibi","year":"2004","unstructured":"Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004 May;65(5):1914-26 | PubMed |","journal-title":"Kidney Int","ISSN":"https:\/\/id.crossref.org\/issn\/0085-2538","issn-type":"print"},{"issue":"1","key":"ref29","first-page":"134","article-title":"Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer.","volume":"13","author":"Raggi","year":"2004","unstructured":"Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis. 2004 Jan;13(1):134-41 | PubMed |","journal-title":"J Heart Valve Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0966-8519","issn-type":"print"},{"key":"ref30","first-page":"502A","article-title":"Sevelamer preserves and calcium reduces trabecular bone mineral density.","volume":"14","author":"Raggi","year":"2003","unstructured":"Raggi P, Burke SK, Chasan-Taber S, Chertow GM, Holzer H, Bommer J. Sevelamer preserves and calcium reduces trabecular bone mineral density. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2003; 14:502A-502A | Link |","journal-title":"J Am Soc Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1046-6673","issn-type":"print"},{"issue":"5","key":"ref31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1359\/JBMR.041221","article-title":"Decrease in Thoracic Vertebral Bone Attenuation with Calcium-Based Phosphate Binders in Hemodialysis.","volume":"20","author":"Raggi","year":"2005","unstructured":"Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, et al. Decrease in Thoracic Vertebral Bone Attenuation with Calcium-Based Phosphate Binders in Hemodialysis. Journal of Bone and Mineral Research. 2005;20(5):764-772 | Link |","journal-title":"J Bone Miner Res","ISSN":"https:\/\/id.crossref.org\/issn\/0884-0431","issn-type":"print"},{"issue":"10","key":"ref32","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.","volume":"72","author":"Russo","year":"2007","unstructured":"Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007 Nov;72(10):1255-61 | PubMed |","journal-title":"Kidney Int","ISSN":"https:\/\/id.crossref.org\/issn\/0085-2538","issn-type":"print"},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.","volume":"18","author":"Sadek","year":"2003","unstructured":"Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant. 2003 Mar;18(3):582-8 | PubMed |","journal-title":"Nephrol Dial Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0931-0509","issn-type":"print"},{"issue":"6","key":"ref34","first-page":"785","article-title":"Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.","volume":"25","author":"Shaheen","year":"2004","unstructured":"Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J. 2004 Jun;25(6):785-91. | PubMed |","journal-title":"Saudi Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0379-5284","issn-type":"print"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5414\/CNP74012","article-title":"Impact of phosphate binder type on coronary artery calcification in hemodialysis patients.","volume":"74","author":"Shantouf","year":"2010","unstructured":"Shantouf R, Ahmadi N, Flores F, Tiano J, Gopal A, Kalantar-Zadeh K, et al. Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol. 2010 Jul;74(1):12-8 | PubMed |","journal-title":"Clin Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/0301-0430","issn-type":"print"},{"key":"ref36","first-page":"22","article-title":"A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone. Three-years follow up.","volume-title":"World Congress of Nephrology","author":"Shibata","year":"2009","unstructured":"Shibata K, Iwamoto T, Ono S, Murakami T, Yanagi M, Koguchi N. A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone. Three-years follow up. World Congress of Nephrology. 2009 May: 22-26. | Link |"},{"issue":"1","key":"ref37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","article-title":"RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.","volume":"55","author":"Slatopolsky","year":"1999","unstructured":"Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999 Jan;55(1):299-307 | PubMed |","journal-title":"Kidney Int","ISSN":"https:\/\/id.crossref.org\/issn\/0085-2538","issn-type":"print"},{"issue":"3","key":"ref38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.","volume":"51","author":"St Peter","year":"2008","unstructured":"St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008 Mar;51(3):445-54 | CrossRef | PubMed |","journal-title":"Am J Kidney Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0272-6386","issn-type":"print"},{"issue":"6","key":"ref39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1440-1797.2004.00338.x","article-title":"Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.","volume":"9","author":"Sturtevant","year":"2004","unstructured":"Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, et al. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology (Carlton). 2004 Dec;9(6):406-13 | PubMed |","journal-title":"Nephrology (Carlton)","ISSN":"https:\/\/id.crossref.org\/issn\/1320-5358","issn-type":"print"},{"issue":"1","key":"ref40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.jrn.2007.10.019","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.","volume":"18","author":"Suki","year":"2008","unstructured":"Suki WN; Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr. 2008 Jan;18(1):91-8 | PubMed |","journal-title":"J Ren Nutr","ISSN":"https:\/\/id.crossref.org\/issn\/1051-2276","issn-type":"print"},{"issue":"9","key":"ref41","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.","volume":"72","author":"Suki","year":"2007","unstructured":"Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007 Nov;72(9):1130-7 | PubMed |","journal-title":"Kidney Int","ISSN":"https:\/\/id.crossref.org\/issn\/0085-2538","issn-type":"print"},{"key":"ref42","volume-title":"Zabaneh Cangiano J The DCOR Trial","author":"Suki","year":"2005","unstructured":"Suki WR, Zabaneh, Cangiano J. The DCOR Trial: a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. American Society of Nephrology. 2005"},{"issue":"4","key":"ref43","doi-asserted-by":"publisher","first-page":"c278","DOI":"10.1159\/000127361","article-title":"Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.","volume":"108","author":"Takei","year":"2008","unstructured":"Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108(4):c278-83 | CrossRef | PubMed |","journal-title":"Nephron Clin Pract","ISSN":"https:\/\/id.crossref.org\/issn\/1660-2110","issn-type":"print"},{"issue":"6","key":"ref44","doi-asserted-by":"publisher","first-page":"934","DOI":"10.2215\/CJN.12891211","article-title":"Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.","volume":"7","author":"Vlassara","year":"2012","unstructured":"Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012 Jun;7(6):934-42 | CrossRef | PubMed |","journal-title":"Clin J Am Soc Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/1555-9041","issn-type":"print"},{"issue":"6","key":"ref45","first-page":"381","article-title":"Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.","volume":"50","author":"Wilkes","year":"1998","unstructured":"Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol. 1998 Dec;50(6):381-6 | PubMed |","journal-title":"Clin Nephrol","ISSN":"https:\/\/id.crossref.org\/issn\/0301-0430","issn-type":"print"},{"issue":"4","key":"ref46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1081\/JDI-65259","article-title":"Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.","volume":"27","author":"Yamada","year":"2005","unstructured":"Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail. 2005;27(4):361-5 | PubMed |","journal-title":"Ren Fail","ISSN":"https:\/\/id.crossref.org\/issn\/0886-022X","issn-type":"print"},{"issue":"2","key":"ref47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.","volume":"59","author":"Yilmaz","year":"2012","unstructured":"Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis. 2012 Feb;59(2):177-85 | CrossRef | PubMed |","journal-title":"Am J Kidney Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0272-6386","issn-type":"print"},{"key":"ref48","unstructured":"Zhao H, Wang JD, Zhao DM, Dong YM, Gao Y. Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end-stage renal disease: A randomized controlled trial. Chinese Journal of Evidence-Based Medicine. 2014;14(11):1293-1298. | Link | Eknoyan G, Lameire N, Eckardt KU, Kasiske BL, Wheeler DC, Levin A, et al. (2013). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int, 3, 5-14 | Link | Kopple JD. (2001). National kidney foundation K\/DOQI clinical practice guidelines for nutrition in chronic renal failure. American journal of kidney diseases, 37(1), S66-S70 | Link | Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. CMAJ: Canadian Medical Association Journal, 179(11), 1154\u20131162 | CrossRef |"}],"container-title":["Medwave"],"original-title":["Sevelamer comparado con quelantes de f\u00f3sforo en base a calcio para la insuficiencia renal cr\u00f3nica"],"link":[{"URL":"http:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T02:24:50Z","timestamp":1602123890000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medwave.cl\/link.cgi\/Medwave\/PuestaDia\/ResEpis\/6942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,17]]},"references-count":49,"journal-issue":{"issue":"Suppl2","published-online":{"date-parts":[[2017,5,17]]}},"URL":"https:\/\/doi.org\/10.5867\/medwave.2017.6942","relation":{},"ISSN":["0717-6384"],"issn-type":[{"value":"0717-6384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,17]]}}}